vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Eastern Bankshares, Inc. (EBC). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 11.1%, a 10.9% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 29.6%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
ANIP vs EBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $295.9M |
| Net Profit | $27.5M | $65.3M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 22.1% |
| Revenue YoY | 29.6% | 710.6% |
| Net Profit YoY | 367.5% | -34.4% |
| EPS (diluted) | $1.14 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $295.9M | ||
| Q4 25 | $247.1M | $37.5M | ||
| Q3 25 | $227.8M | $241.5M | ||
| Q2 25 | $211.4M | $244.9M | ||
| Q1 25 | $197.1M | $31.1M | ||
| Q4 24 | $190.6M | $216.5M | ||
| Q3 24 | $148.3M | $203.4M | ||
| Q2 24 | $138.0M | $154.0M |
| Q1 26 | — | $65.3M | ||
| Q4 25 | $27.5M | $99.5M | ||
| Q3 25 | $26.6M | $106.1M | ||
| Q2 25 | $8.5M | $100.2M | ||
| Q1 25 | $15.7M | $-217.7M | ||
| Q4 24 | $-10.3M | $60.8M | ||
| Q3 24 | $-24.2M | $-6.2M | ||
| Q2 24 | $-2.3M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 38.9% | ||
| Q2 25 | 6.6% | 41.0% | ||
| Q1 25 | 13.3% | -590.9% | ||
| Q4 24 | -2.3% | 33.3% | ||
| Q3 24 | -13.8% | -1.6% | ||
| Q2 24 | 3.7% | 24.7% |
| Q1 26 | — | 22.1% | ||
| Q4 25 | 11.1% | 265.6% | ||
| Q3 25 | 11.7% | 44.0% | ||
| Q2 25 | 4.0% | 40.9% | ||
| Q1 25 | 8.0% | -699.2% | ||
| Q4 24 | -5.4% | 28.1% | ||
| Q3 24 | -16.3% | -3.0% | ||
| Q2 24 | -1.7% | 17.1% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $1.14 | $0.48 | ||
| Q3 25 | $1.13 | $0.53 | ||
| Q2 25 | $0.36 | $0.50 | ||
| Q1 25 | $0.69 | $-1.08 | ||
| Q4 24 | $-0.45 | $0.29 | ||
| Q3 24 | $-1.27 | $-0.03 | ||
| Q2 24 | $-0.14 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $551.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $4.3B |
| Total Assets | $1.4B | $30.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $551.7M | ||
| Q4 25 | $285.6M | $507.6M | ||
| Q3 25 | $262.6M | $703.4M | ||
| Q2 25 | $217.8M | $948.3M | ||
| Q1 25 | $149.8M | $609.0M | ||
| Q4 24 | $144.9M | $1.9B | ||
| Q3 24 | $145.0M | $1.7B | ||
| Q2 24 | $240.1M | $1.4B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $540.7M | $4.3B | ||
| Q3 25 | $505.8M | $3.8B | ||
| Q2 25 | $436.8M | $3.7B | ||
| Q1 25 | $418.6M | $3.6B | ||
| Q4 24 | $403.7M | $3.6B | ||
| Q3 24 | $405.9M | $3.7B | ||
| Q2 24 | $455.8M | $3.0B |
| Q1 26 | — | $30.6B | ||
| Q4 25 | $1.4B | $30.6B | ||
| Q3 25 | $1.4B | $25.5B | ||
| Q2 25 | $1.3B | $25.5B | ||
| Q1 25 | $1.3B | $25.0B | ||
| Q4 24 | $1.3B | $25.6B | ||
| Q3 24 | $1.3B | $25.5B | ||
| Q2 24 | $920.8M | $21.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $432.4M | ||
| Q3 25 | $44.1M | $157.1M | ||
| Q2 25 | $75.8M | $123.9M | ||
| Q1 25 | $35.0M | $47.3M | ||
| Q4 24 | $15.9M | $283.8M | ||
| Q3 24 | $12.5M | $108.3M | ||
| Q2 24 | $17.4M | $54.3M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 4.35× | ||
| Q3 25 | 1.66× | 1.48× | ||
| Q2 25 | 8.87× | 1.24× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 4.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
EBC
Segment breakdown not available.
